Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...
BridgeBio Oncology Therapeutics (BBOT) targets KRAS and PI3Ka malignancies with next-generation small molecule therapeutics, ...
Pfizer Inc. (NYSE:PFE) today provided its full-year 2026 guidance (2) while revising its November 4, 2025 full-year 2025 Revenue guidance (2) and reaffirming all other components of full-year 2025 ...
Pfizer Inc. forecast little to no sales growth next year as the drugmaker undertakes an effort to refresh its pipeline of hit ...
Pfizer announces Tukysa added to first-line maintenance therapy extends median PFS by over 8 months in patients with HER2+ metastatic breast cancer: New York Friday, December 12, ...
Retired Army Col. Ronald Poropatich, MD, presented a scenario during his “Medical Autonomous Care & Autonomous Movement” ...
Retired Army Col. Dr. Ronald Poropatich presented a scenario during his “Medical Autonomous Care & Autonomous Movement” ...
Pfizer Inc. (NYSE:PFE) today provided its full-year 2026 guidance(2) while revising its November 4, 2025 full-year 2025 Revenue guidance(2) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results